Latest News & Blog

Inspiring & original thinking. And, the latest news about us.

THINKING

Welcome to Well Filtered™

A blog series dedicated to unearthing the ideas, perspectives, and innovations that matter most in kidney health.

Can Early-Stage Risk Assessment Tools be the Game-changer in Kidney Care? A quick Q&A with UCLA’s Dr. Keith Norris. 12.15.22

The importance of earlier stage kidney care and why PCPs are the key. A quick Q&A with UCLA’s Dr. Keith Norris. 12.07.22

Why we need to remove race from kidney function equations. A quick Q&A with UCLA’s Dr. Keith Norris. 11.17.22

Should race ever play a role in health care? Find out what UCLA’s Dr. Keith Norris has to say. 11.01.22

Getting FDA approval, a base hit. Getting reimbursement, that’s the ball game. 06.28.22

Is there real value in value-based care? 02.08.22

A SPECIAL, NEW YEAR INVESTIGATIVE BLOG: Making Sense of Population Health, Precision Medicine & Value-Based Care with Mount Sinai’s Dr. Arshad Rahim 01.06.22

An “Inside Look” at Precision Medicine, Cardiovascular & Kidney Disease: We Get It Straight from Bayer’s, Dr. Amit Sharma 10.26.21

A “How To” Playbook for Disrupting Kidney Care: Our Live Chat with the National Kidney Foundation’s Chief Medical Officer 09.20.21

Are Kidney-Focused Clinical Studies Finally Hitting Their Groove? The Trials to Watch & Why 08.10.21

3 Ways We’re Translating Lessons Learned in Cancer to Help Fix the Kidney Care Model 7.27.21

6 Tipping Point Innovations in Kidney Care: A Leading Expert Shares His POV 6.28.21

Why a Shift in Thinking from Kidney Disease to Kidney Health is Mission-Critical. A Candid Conversation with NKF’S Former President & Board Member, Holly Kramer. 6.02.21

NEWS

U.S. CPT® Code Granted for KidneyIntelX™ 07.01.19
CPT Code a key component for reimbursement from private medical insurance and Medicare NEW YORK, July 1, 2019 /PRNewswire/ -- Renalytix AI plc (LON: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today that the American Medical

Read More
Study Published in Journal of Clinical Investigation Insight Demonstrates Ability to Predict Early Rejection in Kidney Transplant with FractalDx Portfolio Technology 06.07.19
Positive study results support successful development of a predictive blood test for transplant patients to meet critical unmet medical need NEW YORK, June 7, 2019 /PRNewswire/ -- Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease,

Read More
RenalytixAI Expands Core Investigator Group for Kidney Transplant Advanced Diagnostic Program 05.21.19
Investigators now include transplant experts from University of Oxford, Yale School of Medicine, Emory University School of Medicine, Icahn School of Medicine at Mount Sinai, University of Manitoba, Westmead Hospital Sydney, University of Alabama at Birmingham, and Cleveland Clinic NEW YORK, May

Read More
RenalytixAI and University Medical Center Groningen to Evaluate KidneyIntelX™ for Early Identification and Guiding Therapeutic Treatment of Diabetic Kidney Disease 05.07.19
NEW YORK, May 7, 2019 /PRNewswire/ -- Renalytix AI plc (LON: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today a collaboration with University Medical Center Groningen (UMCG), Netherlands, to evaluate KidneyIntelX™ across over 3,500

Read More
FDA Grants Breakthrough Device Designation to KidneyIntelX™ 05.02.19
Provides Priority Regulatory Review of AI-Enabled Diagnostic for Fast-Progressing Kidney Disease NEW YORK, May 2, 2019 /PRNewswire/ -- Renalytix AI plc (LON: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today that it has been granted

Read More
RenalytixAI Forms Core Investigator Group for Kidney Transplant Advanced Diagnostic Program 03.22.19
Investigators include leading transplant clinicians from Emory University, the University of Manitoba, the Westmead Hospital Sydney, and Icahn School of Medicine at Mount Sinai NEW YORK, March 22, 2019 /PRNewswire/ -- Renalytix AI plc (LON: RENX), a developer of artificial intelligence-enabled

Read More
RenalytixAI and AKESOgen In Joint Venture Partnership for Expanded Testing Capacity and Pharma Services 02.13.19
NEW YORK, Feb. 13, 2019 /PRNewswire/ -- RenalytixAI (AIM: RENX), a developer of artificial intelligence-enabled diagnostics for kidney disease, today announced the completion of a joint venture partnership agreement with AKESOgen, an industry-leading commercial laboratory facility and provider of

Read More
RenalytixAI Expands Leadership Team to Support Launch of AI-Enabled Diagnostics for Kidney Disease 02.06.19
Company Adds Clinical and Data Security Expertise to Support KidneyIntelX Clinical Validation, Software and Regulatory Programs NEW YORK, Feb. 6, 2019 /PRNewswire/ -- Renalytix AI plc (LON: RENX), a developer of artificial intelligence-enabled diagnostics for kidney disease, today announced the

Read More
RenalytixAI Initiates Clinical Validation Study of AI-Enabled KidneyIntelX™ for Diagnosing Fast-Progressing Kidney Disease 01.23.19
Validation study to assess approximately 5,000 patients with participation from a multi-center group of leading U.S. investigators NEW YORK, Jan. 23, 2019 /PRNewswire/ -- Renalytix AI plc (LON: RENX), a developer of artificial intelligence-enabled diagnostics for kidney disease, today announced

Read More
RenalytixAI Raises $29 Million to Commercialize AI-Enabled Clinical Diagnostic Solutions for Kidney Disease 11.15.18
Solutions to Improve Detection, Management and Treatment of Kidney Disease, Which Impacts More Than 850 Million Globally Mount Sinai to Collaborate for Launch of Initial Product, KidneyIntelX™, in 2019 NEW YORK, Nov. 15, 2018 /PRNewswire/ -- Renalytix AI plc (LSE AIM: RENX), a developer of

Read More

...